# Comparative phenotypic and molecular profiling of replicative and chemically-induced senescence in articular chondrocytes

**Authors:** Maria Belen Arteaga, Karyna Tarasova, Angkana Kidtiwong, Sinan Gültekin, Iris Gerner, Florien Jenner

PMC · DOI: 10.1038/s41420-026-02961-y · 2026-02-23

## TL;DR

This study compares different ways to induce cell aging in cartilage cells to better understand osteoarthritis and improve research models.

## Contribution

The study identifies distinct molecular and phenotypic features of different senescence models in chondrocytes, highlighting mitochondrial dysfunction as a central mechanism.

## Key findings

- All senescence models showed cell cycle arrest, increased SA-β-gal activity, and mitochondrial dysfunction.
- DOX induced DNA damage and apoptosis, while DEX caused senescence without significant ROS or apoptosis.
- Transcriptomics and proteomics revealed divergent secretory profiles and pathway alterations between models.

## Abstract

Osteoarthritis (OA) is a degenerative joint disease characterized by the accumulation of senescent chondrocytes, which drive inflammation and cartilage degradation. However, in vitro models often fail to recapitulate the complexity of OA-associated senescence. This study compares three senescence induction strategies in chondrocytes—replicative senescence (HP), and stress-induced premature senescence (SIPS) via doxorubicin (DOX) and dexamethasone (DEX)—to establish a physiologically relevant in vitro model for OA research. To this end ovine chondrocytes (n = 3) were subjected to serial passaging (to P40) or exposed to optimized concentrations of DOX (50 nM) or DEX (1 µM). Low passage (P3) cells served as controls. Cellular senescence was assessed via proliferation assays, cell cycle analysis, SA-β-gal activity, telomere length, ROS levels, mitochondrial function, transcriptomic profiling (NGS), and high-resolution mass spectrometry proteomic analysis. All models induced key senescence hallmarks including cell cycle and proliferation arrest, increased SA-β-gal activity, and mitochondrial dysfunction. HP cells showed telomere shortening, ROS accumulation, ATP depletion, and SASP secretion. DOX induced strong DNA damage responses and elevated apoptosis markers, while DEX induced senescence without significant ROS or apoptosis, suggesting distinct SIPS mechanisms. Transcriptomics revealed convergent downregulation of oxidative phosphorylation and selenoamino acid metabolism pathways, implicating mitochondrial dysfunction and redox imbalance as shared features. However, HP induced broad transcriptional suppression, also of inflammatory pathways, while DOX and DEX activated immune and SASP-related pathways. Proteomics confirmed divergent secretory profiles, with DOX/DEX increasing SASP-factors and HP enriching matrix proteins. In summary, although all models recapitulate fundamental aspects of senescence, they diverge in stress responses, immune signaling, and apoptosis profiles. HP most closely mimics aging-associated senescence, whereas DOX and DEX model distinct SIPS relevant to oxidative or pharmacological stress. These findings underscore the importance of model selection in senescence-focused OA research and highlight mitochondrial dysfunction as a central mechanistic hub across senescence pathways.

## Linked entities

- **Chemicals:** doxorubicin (PubChem CID 31703), dexamethasone (PubChem CID 5743)
- **Diseases:** Osteoarthritis (MONDO:0005178)

## Full-text entities

- **Genes:** SPON1 (spondin 1) [NCBI Gene 10418] {aka VSGP/F-spondin, f-spondin}, PRKCD (protein kinase C delta) [NCBI Gene 5580] {aka ALPS3, CVID9, MAY1, PKCD, nPKC-delta}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, PTX3 (pentraxin 3) [NCBI Gene 5806] {aka TNFAIP5, TSG-14}, COMP (cartilage oligomeric matrix protein) [NCBI Gene 1311] {aka CTS2, EDM1, EPD1, MED, PSACH, THBS5}, ND5 (NADH dehydrogenase subunit 5) [NCBI Gene 4540] {aka MTND5}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, NR3C1 (nuclear receptor subfamily 3 group C member 1) [NCBI Gene 2908] {aka GCCR, GCR, GCRST, GR, GRL}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, SOD3 (superoxide dismutase 3) [NCBI Gene 6649] {aka EC-SOD}, B2M (beta-2-microglobulin) [NCBI Gene 567] {aka AMYLD6, IMD43, MHC1D4}, FBLN2 (fibulin 2) [NCBI Gene 2199], CHUK (component of inhibitor of nuclear factor kappa B kinase complex) [NCBI Gene 1147] {aka BPS2, IKBKA, IKK-1, IKK-alpha, IKK1, IKKA}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, COL14A1 (collagen type XIV alpha 1 chain) [NCBI Gene 7373] {aka UND}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, IGFBP5 (insulin like growth factor binding protein 5) [NCBI Gene 3488] {aka IBP5}, EDIL3 (EGF like and discoidin domains 3) [NCBI Gene 10085] {aka DEL1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, RPLP0 (ribosomal protein lateral stalk subunit P0) [NCBI Gene 6175] {aka L10E, LP0, P0, PRLP0, RPP0, uL10}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, CYTB (cytochrome b) [NCBI Gene 4519] {aka MTCYB}, ND6 (NADH dehydrogenase subunit 6) [NCBI Gene 4541] {aka MTND6}, CDKN2AIP (CDKN2A interacting protein) [NCBI Gene 55602] {aka XTBD2}, TNN (tenascin N) [NCBI Gene 63923] {aka TN-W, TNW}, TOP2A (DNA topoisomerase II alpha) [NCBI Gene 7153] {aka TOP2, TOP2alpha, TOPIIA, TP2A}, GLB1 (galactosidase beta 1) [NCBI Gene 2720] {aka EBP, ELNR1, MPS4B}, IGFBP2 (insulin like growth factor binding protein 2) [NCBI Gene 3485] {aka IBP2, IGF-BP53}
- **Diseases:** cartilage (MESH:D002357), OA (MESH:D010003), mitochondrial dysregulation (MESH:D021081), pain (MESH:D010146), Mitochondrial dysfunction (MESH:D028361), articular inflammation (MESH:D007249), degenerative joint disease (MESH:D019636), musculoskeletal disease (MESH:D009140), chronic (MESH:D002908), selenium deficiency (MESH:D007153), stiffness (MESH:C566112), HP (MESH:C537262), SIPS (MESH:D000079225), osteoarthritic joint (MESH:D007592)
- **Chemicals:** MitoTracker  Green FM (MESH:C111472), butorphanol (MESH:D002077), TRIzol (MESH:C411644), isopropanol (MESH:D019840), thiopental (MESH:D013874), Phalloidin (MESH:D010590), Triton X-100 (MESH:D017830), detomidine (MESH:C041255), tetracaine hydrochloride (MESH:D013748), chloroform (MESH:D002725), mebezonium iodide (MESH:C059325), ATP (MESH:D000255), glutathione (MESH:D005978), DAPI (MESH:C007293), ROS (MESH:D017382), Pen (MESH:C058388), DOX (MESH:D004317), sodium citrate (MESH:D000077559), DCF (MESH:D015649), embutramide (MESH:C059324), superoxide (MESH:D013481), CellTiter-Glo  2.0 (-), PI (MESH:D011419), Alexa Fluor 488 (MESH:C000711379), Selenium (MESH:D012643), DEX (MESH:D003907), MTT (MESH:C070243)
- **Species:** Ovis aries (domestic sheep, species) [taxon 9940], Hepacivirus P (species) [taxon 2202225], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** LP — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_B7PY), HP — Homo sapiens (Human), Fibrosarcoma, Cancer cell line (CVCL_3715)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966285/full.md

---
Source: https://tomesphere.com/paper/PMC12966285